ESBRIET (pirfenidone), immunosuppressant

• ESBRIET has Marketing Authorisation in the treatment of mild to moderate idiopathic pulmonary fibrosis.
• The efficacy of ESBRIET versus placebo has been demonstrated in an improvement in predicted forced vital capacity: the level of the effect is moderate and its efficacy as regards mortality must be viewed with caution given the numerous methodological limitations.
• It represents only a minor improvement in patients with a forced vital capacity (FVC) ≥ 50% and diffusing capacity for carbon monoxide (DL_CO) ≥ 30%.
• Use of ESBRIET necessitates regular monitoring of tolerability and liver enzymes, as well as stopping smoking.

-